Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2007

JDRF and Lilly Are Joining Forces to Back Research on Diabetes-Related Biomarkers

  • The Juvenile Diabetes Research Foundation (JDRF) and Eli Lilly have established an initiative to accelerate discovery and development of a cure for diabetes through biomarker research.

    The effort, called the JDRF-Lilly Innovative and Academic Research and Development Grants in Diabetes Biomarkers, will be stimulated by a $3 million award over three years from the Lilly Foundation to JDRF.

    This JDRF-Lilly will support research on biomarkers for pancreatic beta cell mass and function. Both academic and commercial scientists can apply for grants from this initiative. The review process, under the auspices of JDRF, will include both peer scientific review and lay review committees. Those awarded Academic Research and Development grants, will be matched with specific scientific targets.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »